{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:28:28Z","timestamp":1782833308296,"version":"3.54.5"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY014943"],"award-info":[{"award-number":["EY014943"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ajo.2019.03.024","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T21:47:54Z","timestamp":1554241674000},"page":"377-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors"],"prefix":"10.1016","volume":"223","author":[{"given":"John H.","family":"Kempen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosne","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonetta D.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L.","family":"Liesegang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Payal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazlee","family":"Zebardast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali P.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"Levy-Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Nussenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Suhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/bjo.60.3.192","article-title":"Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis","volume":"60","author":"McGavin","year":"1976","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0161-6420(94)31325-X","article-title":"Severity of scleritis and episcleritis","volume":"101","author":"Sainz de la Maza","year":"1994","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0161-6420(97)30361-3","article-title":"Scleritis-associated uveitis","volume":"104","author":"Sainz de la Maza","year":"1997","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archopht.120.1.15","article-title":"Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy","volume":"120","author":"Sainz de la Maza","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(91)32269-3","article-title":"Progression of scleral disease","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.024_bib9","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0161-6420(93)31473-9","article-title":"An analysis of therapeutic decision for scleritis","volume":"100","author":"Sainz de la","year":"1993","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.024_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/bjophthalmol-2017-311610","article-title":"Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial","volume":"102","author":"O'Neil","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2014.12.009","article-title":"Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I\/II clinical trial","volume":"159","author":"Bhatt","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.03.024_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","article-title":"Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I\/II clinical trial","volume":"172","author":"Knickelbein","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib13","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib14","first-page":"217","article-title":"Use of topical steroid therapy in the management of nonnecrotizing anterior scleritis","volume":"34","author":"McMullen","year":"1999","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.024_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bjo.50.8.463","article-title":"Double-blind trial of the treatment of episcleritis-scleritis with oxyphenbutazone or prednisolone","volume":"50","author":"Watson","year":"1966","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib17","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ophtha.2005.05.008","article-title":"Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis","volume":"112","author":"Albini","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.024_bib18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ophtha.2011.02.043","article-title":"Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis","volume":"118","author":"Sohn","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2009.07.035","article-title":"Evaluation of sub-Tenon triamcinolone acetonide injections in the treatment of scleritis","volume":"149","author":"Johnson","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0161-6420(01)01020-X","article-title":"Discussion by Douglas A. Jabs, MD, MBA","volume":"109","author":"Jabs","year":"2002","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib21","first-page":"805","article-title":"Discussion by Emmett T. Cunningham, Jr. , MD, MPH, PhD","volume":"109","author":"Cunningham","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2019.03.024_bib22","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.mog.0000153314.51198.58","article-title":"Nonsteroidal antiinflammatory drugs and the small intestine","volume":"21","author":"Fortun","year":"2005","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2014.08.024","article-title":"Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study","volume":"122","author":"Yates","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2019.03.024_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"19","key":"10.1016\/j.ajo.2019.03.024_bib26","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ajo.2019.03.024_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.024_bib28","first-page":"6031","article-title":"Incidence and risk factors for ocular hypertension in adults with non-infectious uveitis","volume":"55","author":"Daniel","year":"2014","journal-title":"ARVO Meeting Abstracts"},{"key":"10.1016\/j.ajo.2019.03.024_bib29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","article-title":"The risk of intraocular pressure elevation in pediatric non-infectious uveitis","volume":"122","author":"Kothari","year":"2015","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.ajo.2019.03.024_bib30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2019.03.024_bib31","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ophtha.2014.04.022","article-title":"Cost-Effectiveness of Fluocinolone Acetonide Implant versus Systemic Therapy for Noninfectious Intermediate, Posterior, and Panuveitis","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.024_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2015.12.034","article-title":"Remission of Intermediate Uveitis: Incidence and Predictive Factors","volume":"164","author":"Kempen","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.exer.2006.11.011","article-title":"Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin","volume":"84","author":"Kohno","year":"2007","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08916934.2015.1027818","article-title":"The role of statins in inflammatory vasculitides","volume":"48","author":"Tremoulet","year":"2015","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ajo.2015.01.009","article-title":"Association between statin use and uveitis: results from the Pacific Ocular Inflammation study","volume":"159","author":"Borkar","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.024_bib38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1080\/02713683.2017.1355468","article-title":"Simvastatin as an adjunct to conventional therapy of non-infectious uveitis: a randomized, open-label pilot study","volume":"42","author":"Shirinsky","year":"2017","journal-title":"Curr Eye Res"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.024_bib39","doi-asserted-by":"crossref","first-page":"e0168312","DOI":"10.1371\/journal.pone.0168312","article-title":"Atorvastatin, losartan and captopril lead to upregulation of TGF-beta, and downregulation of IL-6 in coronary artery disease and hypertension","volume":"11","author":"Sepehri","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joco.2016.09.009","article-title":"Therapeutic targets of renin-angiotensin system in ocular disorders","volume":"29","author":"Choudhary","year":"2017","journal-title":"J Curr Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.exer.2006.03.005","article-title":"Captopril suppresses inflammation in endotoxin-induced uveitis in rats","volume":"83","author":"Ilieva","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2019.03.024_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-9255-7-21","article-title":"Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB","volume":"7","author":"Miguel-Carrasco","year":"2010","journal-title":"J Inflamm (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2019.03.024_bib43","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Kacmaz","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.024_bib45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2019.03.024_bib46","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ophtha.2009.07.025","article-title":"Hypopyon in patients with uveitis","volume":"117","author":"Zaidi","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.024_bib48","first-page":"576","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"3","author":"Kacmaz","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib49","first-page":"423","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"AmJOphthalmol"},{"key":"10.1016\/j.ajo.2019.03.024_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12177-009-9044-4","article-title":"Ocular disease in patients with ANCA-positive vasculitis","volume":"3","author":"Watkins","year":"2009","journal-title":"J Ocul Biol Dis Infor"},{"issue":"7","key":"10.1016\/j.ajo.2019.03.024_bib51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjo.2009.174466","article-title":"Adverse effects of smoking on patients with ocular inflammation","volume":"94","author":"Galor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib52","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ophtha.2011.02.044","article-title":"Risk of relapse in primary acute anterior uveitis","volume":"118","author":"Grunwald","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/09273948.2011.646382","article-title":"High-dose intravenous corticosteroids for ocular inflammatory diseases","volume":"20","author":"Charkoudian","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.024_bib54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ophtha.2012.01.043","article-title":"Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases","volume":"119","author":"Udoetuk","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2019.03.024_bib55","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.ophtha.2012.05.032","article-title":"Risk of hypotony in noninfectious uveitis","volume":"119","author":"Daniel","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.024_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","article-title":"Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study","volume":"120","author":"Gregory","year":"2013","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.024_bib57","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3899\/jrheum.121180","article-title":"Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors","volume":"40","author":"Lerman","year":"2013","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib58","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ajo.2013.04.040","article-title":"Risk of choroidal neovascularization among the uveitides","volume":"156","author":"Baxter","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.024_bib59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ophtha.2013.09.041","article-title":"Factors predictive of remission of new-onset anterior uveitis","volume":"121","author":"Artornsombudh","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib61","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ophtha.2015.10.056","article-title":"Risk of retinal neovascularization in cases of uveitis","volume":"123","author":"Patel","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2019.03.024_bib62","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ophtha.2017.03.041","article-title":"Risk of ocular hypertension in adults with noninfectious uveitis","volume":"124","author":"Daniel","year":"2017","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib63","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","article-title":"The risk of intraocular pressure elevation in pediatric noninfectious uveitis","volume":"122","author":"Kothari","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for ocular inflammation","volume":"25","author":"Durrani","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib66","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.024_bib67","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.024_bib68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11892-017-0910-3","article-title":"Intraocular inflammation in diabetic populations","volume":"17","author":"Kheir","year":"2017","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ajo.2019.03.024_bib69","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ajo.2019.03.024_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","article-title":"Methods for identifying 30 chronic conditions: application to administrative data","volume":"15","author":"Tonelli","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"10.1016\/j.ajo.2019.03.024_bib71","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2015.02.034","article-title":"Association between smoking and uveitis: results from the pacific ocular inflammation study","volume":"122","author":"Yuen","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib72","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ophtha.2009.08.011","article-title":"Cigarette smoking as a risk factor for uveitis","volume":"117","author":"Lin","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2019.03.024_bib73","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ajo.2007.12.032","article-title":"Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis","volume":"145","author":"Thorne","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.024_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09273941003739928","article-title":"Rituximab treatment for persistent scleritis associated with rheumatoid arthritis","volume":"18","author":"Iaccheri","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.ajo.2019.03.024_bib75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09273940802331643","article-title":"Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis","volume":"16","author":"Onal","year":"2008","journal-title":"Ocul Immunol Inflamm"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419301345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419301345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:47:20Z","timestamp":1757598440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419301345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":75,"alternative-id":["S0002939419301345"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.024","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}